Treatment outcomes of diffuse large B-cell non-Hodgkin{u2019}s lymphoma presenting to Tanta cancer center /
Ayman Elsayed Elfakharany
Treatment outcomes of diffuse large B-cell non-Hodgkins lymphoma presenting to Tanta cancer center / نتائج علاج أورام الغدد الليمفاوية اللاهودجكنية المتسعة كبيرة الخلية من النوع باء في مركز أورام طنطا Ayman Elsayed Elfakharany ; Supervised Ahmed Abdelmabood Zeeneldin , Ayman Abdelsamie Gaber , Amgad Ahmad Shaheen - Cairo : Ayman Elsayed Elfakharany , 2014 - 155 P. : charts ; 25cm
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Medical Oncology
Introduction: DLBC-NHL is the most common lymphoid neoplasm and constitutes almost 50% of all NHLs. Methods: This thesis includes 485 patients was conducted to study the outcomes in patients with DLBC-NHL among patients treated at Tanta Cancer Center (TCC) between 2003 and 2006 and followed up till March 2014. Results: 88% of patients received CTx being CHOP in 72.4% of cases. CR was achieved in 62.1%, PFS was 21.4 months. The median OS was 20 months. Conclusions: Outcomes of DBLC-NHL at TCC is comparable to those in the literature. Adding Rituximab is recommended to further improve the treatment
DLBC Egyptian National Cancer Institute Tanta Cancer Center
Treatment outcomes of diffuse large B-cell non-Hodgkins lymphoma presenting to Tanta cancer center / نتائج علاج أورام الغدد الليمفاوية اللاهودجكنية المتسعة كبيرة الخلية من النوع باء في مركز أورام طنطا Ayman Elsayed Elfakharany ; Supervised Ahmed Abdelmabood Zeeneldin , Ayman Abdelsamie Gaber , Amgad Ahmad Shaheen - Cairo : Ayman Elsayed Elfakharany , 2014 - 155 P. : charts ; 25cm
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Medical Oncology
Introduction: DLBC-NHL is the most common lymphoid neoplasm and constitutes almost 50% of all NHLs. Methods: This thesis includes 485 patients was conducted to study the outcomes in patients with DLBC-NHL among patients treated at Tanta Cancer Center (TCC) between 2003 and 2006 and followed up till March 2014. Results: 88% of patients received CTx being CHOP in 72.4% of cases. CR was achieved in 62.1%, PFS was 21.4 months. The median OS was 20 months. Conclusions: Outcomes of DBLC-NHL at TCC is comparable to those in the literature. Adding Rituximab is recommended to further improve the treatment
DLBC Egyptian National Cancer Institute Tanta Cancer Center